Advanced Biomed Inc. filed a Form 8-K with the SEC on November 20, 2026, disclosing that it entered into a securities purchase agreement on that same date to sell 320,000 shares of common stock at $0.35 per share in a private placement for a total purchase price of $112,000.
Key Highlights
- Shares issued: 320,000 shares of common stock, par value $0.001 per share, sold to certain investors.
- Price per share: $0.35, for a total purchase price of $112,000.
- Transaction structure: Private placement exempt from registration under the U.S. Securities Act of 1933, pursuant to Section 4(a)(2) and Regulation S.
- Emerging growth company: The registrant identified itself as an emerging growth company under Rule 405 of the Securities Act of 1933.
- Signing officer: The report was signed by Xiaomin Chen, Chief Executive Officer, on November 20, 2026.
Advanced Biomed's $112,000 Private Placement: Terms and Structure
According to the filing, Advanced Biomed Inc. (NASDAQ:ADVB), a Nevada corporation headquartered in Tainan City, Taiwan, entered into a securities purchase agreement on November 20, 2026, with certain investors. Under that agreement, the company agreed to issue and sell 320,000 shares of its common stock at a price of $0.35 per share, generating a total purchase price of $112,000, the filing disclosed.
The company reported that the shares were issued in a private placement exempt from the registration requirements of the U.S. Securities Act of 1933, as amended, relying on Section 4(a)(2) of that act and Regulation S promulgated thereunder. The filing noted that the description of the agreement "does not purport to be complete and is qualified in its entirety by reference to the full text of the Securities Purchase Agreements," which was filed as Exhibit 10.1 to the current report.
The filing also stated that the report "does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction." The registrant indicated it had not elected to use the extended transition period for complying with new or revised financial accounting standards available to emerging growth companies.
What Was Disclosed
Advanced Biomed Inc. disclosed the entry into a securities purchase agreement to sell 320,000 common shares at $0.35 each for $112,000 total, in a private placement under Section 4(a)(2) and Regulation S, reported via Form 8-K dated November 20, 2026.



Please wait processing your request...